Clinical Trial Update: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial evaluating VLY-686 for treatment-resistant pruritus associated with atopic dermatitis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• VLY-686

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Treatment-resistant Pruritus Associated With Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-06-11